Imaging to Assess Bone Strength and its Determinants

Similar documents
Beyond BMD: Bone Quality and Bone Strength

Disclosures. Beyond BMD: Bone Quality & Bone Strength. Design of a Structure. Fractures = structural failure of the skeleton

Beyond BMD: Bone Quality and Bone Strength

Beyond BMD: Bone Quality and Bone Strength

Osteoporosis in Men Professor Peter R Ebeling

HRT and Risedronate Combined Anabolic and Antiresorptive Therapy

New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence

7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation

This is a repository copy of Microarchitecture of bone predicts fractures in older women.

AACE Congress Symposium Boston, MA May 20, 2018

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Bone Microarchitecture Assessed by HR-pQCT as Predictor of Fracture Risk in Postmenopausal Women: The OFELY Study

Osteoporosis Screening and Treatment in Type 2 Diabetes

Differentiating Pharmacological Therapies for Osteoporosis

Increased Cortical Porosity in Older Men With Fracture

Osteoporosis in older men is a major public health problem.

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Outline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD

Assessment and Treatment of Osteoporosis Professor T.Masud

OSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION

Least significant changes and monitoring time intervals for high-resolution pqct-derived bone outcomes in postmenopausal women

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA

Upcoming Agents for Osteoporosis

Bone microarchitecture is a determinant of bone strength

Thickness Computation Under In-Vivo Trabecular Bone CT Imaging

# % # & # # ( # ) # % # # ) +,#. # ) / ) 3 ) ) 7 55, # 09 /:2 ;88% 111 <!= <01 9<1:<:1:==

An Update on Osteoporosis Treatments

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Controversies in Osteoporosis Management

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Download slides:

Current and Emerging Strategies for Osteoporosis

Meta-analysis: analysis:

BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE

SKELETAL FRAGILITY AND FRACTURE RISK IN PATIENTS WITH DIABETES

AACE. Osteoporosis Treatment: Then and Now

Updates in Osteoporosis

Trabecular bone analysis with tomosynthesis in diabetic patients: comparison with CT-based finite-element method

2017 Santa Fe Bone Symposium McClung

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis

CIC Edizioni Internazionali. Bone quality and bone strength: benefits of the bone-forming approach. Mini-review

Presenter: 翁家嫻 Venue date:

Task Force Co-Chairs. Members

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014

Osteoporosis: A Tale of 3 Task Forces!

Teriparatide for osteoporosis: importance of the full course

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Modélisation par éléments finis des effets des médicaments sur le remodelage osseux : Approche mécanobiologique

Drug Intervals (Holidays) with Oral Bisphosphonates

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

July 2012 CME (35 minutes) 7/12/2016

IMAGING (T LANG, SECTION EDITOR)

Page 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture

Bone Strength Estimated by Micro-Finite Element Analysis (mfea) Is Heritable and Shares Genetic Predisposition With Areal BMD: The Framingham Study

L.W. Sun 1,2, G. Beller 1, D. Felsenberg 1. Introduction. Original Article. Abstract

Bone Phenotype Assessed by HRpQCT and Associations with Fracture Risk in the GLOW Study

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Disclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck

Current Issues in Osteoporosis

Epidemiology and Consequences of Fractures

Differences in Skeletal Microarchitecture and Strength in African American and White Women

REVIEWS. High-resolution in vivo imaging of bone and joints: a window to microarchitecture

Training Course in Sexual and Reproductive Health Research Geneva, February Osteoporosis. Prof René Rizzoli M.D.

In women who have not been on prior osteoporosis

Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis

ACP Colorado-Evidence Based Management of Osteoporosis

TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Prevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Age changes in the human femoral neck and progression to failure. Functional Adaptation in the Femoral Neck

AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT

Osteoporosis Update. Case 2. Case 1: Monday morning, 8:15

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

UC San Francisco UC San Francisco Previously Published Works

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Management in Older Adults

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

Evaluation of Radius Microstructure and Areal Bone Mineral Density Improves Fracture Prediction in Postmenopausal Women

Assessing Bone Quality in Terms of Bone Mineral Density, Buckling Ratio and Critical Fracture Load

Bare Bones. Use of Systemic Osteoporosis Drugs in Select High Risk Patients Undergoing Spine Surgery

CT Imaging of skeleton in small animals. Massimo Marenzana

Current and Emerging Approaches for Osteoporosis

Forteo (teriparatide) Prior Authorization Program Summary

Abstract. Introduction

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Fractures: Epidemiology and Risk Factors. Osteoporosis in Men (more this afternoon) 1/5 men over age 50 will suffer osteoporotic fracture 7/16/2009

Management of postmenopausal osteoporosis

NEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Breast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Transcription:

Imaging to Assess Bone Strength and its Determinants Mary L. Bouxsein, PhD Harvard Medical School, Boston, MA UCSF Osteoporosis Course 26 July 212 Consultant / advisor: Amgen, Eli Lilly, Merck Research funding: Amgen, Merck Disclosures Determinants of Whole Bone Strength Morphology size (mass) shape (distribution of mass) porosity microarchitecture Properties of Bone Matrix mineralization collagen microdamage Clinical Assessment of Bone Strength Areal BMD by DXA Bone mineral / projected area (g/cm 2 ) Reflects (indirectly) Bone size Mineralization Moderate to strong correlation with whole bone strength (r 2 = 5-9%) Strong predictor of fracture risk in untreated women (Marshall et al, 1996) Bouxsein et al, 1999 Bouxsein, Osteop Int, 23 1

BMD explains > 7% of whole bone strength in ex vivo human cadaver studies BMD has limitations in clinical use Femoral Strength (N) 1 8 6 4 2 Proximal Femur (sideways fall) r 2 =.71Does not distinguish several r 2 =.79 attributes 5 of whole bone strength.2.4.6.8 1 1.2 Femoral Neck BMD (g/cm 2 ) Vertebral (L2) Failure Load (lbs) 6 4 1 Bouxsein 1999 Vertebral body (L2) (compression + forward flexion) 3D geometry 3 Microarchitecture2 Intrinsic properties of bone matrix.2.4.6.8 1 Spine BMD (g/cm 2 ) Less than half of patients who fracture have osteoporosis by BMD testing (ie t-scores > -2.5) Schuit et al, 24; 26; Wainwright et al, JCEM 25 Only half of elderly women with incident hip frx had BMD in osteoporotic range at baseline Association between BMD increase and anti-fracture efficacy varies by treatment and skeletal site Low to moderate: alendronate, risedronate, raloxifene Cummings et al 22; Sarkar et al, 22; Watts 24, 25 Moderate to high: denosumab and strontium ranelate Bruyere et al, 27a,b; Austin et al, 211 Roberts et al, IBMS 29 Moro et al, CTI, 1995 Non-Invasive Imaging SIZE & SHAPE how much? how is it arranged? Bone Turnover Markers Bone Strength BONE REMODELING formation / resorption? MATRIX PROPERTIES mineralization collagen traits Geometry Microarchitecture Bone strength Non-invasive imaging Osteoporosis Drugs, Diet, Exercise, Diseases,. 2

Non-invasive Imaging Approaches Geometry DXA-based Hip Structural Analysis (HSA) Estimating Hip Geometry from 2D DXA Hip Structure Analysis (HSA) Use 2D DXA-data to derive 3D geometry Many HSA variables highly correlated to femoral BMD Requires assumptions that have not been tested in all populations and treatments Image courtesy of TJ Beck, Johns Hopkins Univ Assumptions for Hip Structure Analysis estimating femoral geometry from 2D DXA Constant tissue mineral density Femoral neck & shaft : circular Fixed proportion of cortical and trabecular bone at each site Neck: 6% of mass is cortical Troch: 7% of mass is cortical Shaft: 1% of mass is cortical Geometry Non-invasive Imaging Approaches DXA-based Hip Structural Analysis (HSA) Quantitative computed tomography 3D geometry Trabecular and cortical compartments Zebaze et al, JBMR 27 Beck et al, 1999, 21 3

QCT Age-Related Changes in vbmd and Geometry by 3D-QCT (368 women, 32 men, aged 2-97 yrs; Riggs et al JBMR 24) Lumbar spine Total area Trabecular vbmd % Change, ages 2-9 yrs Women Men +14-54 +15-47 F vs M (P-value).253 <.1 Femoral neck Total area Trabecular vbmd Cortical vbmd +13-56 - 24 +7-45 - 13.557 <.1 <.1 For age regressions: P<.5, P<.5 Lumbar spine Age-Related Changes in vbmd and Geometry by 3D-QCT (368 women, 32 men, aged 2-97 yrs; Riggs et al JBMR 24) Total area Trabecular vbmd Femoral neck Total area Trabecular vbmd Cortical vbmd For age regressions: P<.5, P<.5 % Change, ages 2-9 yrs Women Men +14-54 +13-56 - 24 +15-47 +7-45 - 13 F vs M (P-value).253 <.1.557 <.1 <.1 QCT of Femoral neck and hip fracture risk: Multivariate analyses in MrOS 3358 men > 65 yrs, followed prospectively for frx, 4 hip frx All models adjusted for age, BMI, race, clinic site QCT HR per SD % cortical volume 3.4 (2.3 4.9) Min Fem Neck area (cm 2 ) 1.6 (1.3 2.1) Trab vbmd (g/cm 3 ) 1.6 (1.1 2.3) Black et al, JBMR 28 4

QCT of Femoral neck and hip fracture risk: Multivariate analyses in MrOS 3358 men > 65 yrs, followed prospectively for frx, 4 hip frx All models adjusted for age, BMI, race, clinic site QCT QCT + DXA HR per SD HR per SD % cortical volume 3.4 (2.3 4.9) 2.5 (1.6 3.9) Min Fem Neck area (cm 2 ) 1.6 (1.3 2.1) 1.5 (1.1 2.) Trab vbmd (g/cm 3 ) 1.6 (1.1 2.3) 1.2 (.8 1.9) Fem Neck abmd (g/cm 2 ) 2.1 (1.1-3.9) QCT reveals asymmetry of cortical bone loss at femoral neck 2 yr old 8 yr old Mayhew et al, Lancet 25 4. 3. 2. 1.. Cortical thickness (mm) Sup-Post 25 85 Age 4. 3. 2. 1.. Inf-Ant 25 85 Age Poole et al, JBMR 21 Black et al, JBMR 28 Regional cortical thickness in femoral neck predicts hip fracture better than femoral BMD (AGES-REYKJAVIK study, 143 hip fx, 298 controls) Multivariable regression, Hazard Ratio adjusted for age, ht, wt Women (88 frx, 187 ctrl) Men (55 frx, 111 ctrl) Fem Neck Frx Sup-Ant CtTh 1.6 (1.-2.8) 3.2 (1.8-5.7) FN abmd 1.2 (.7-2.) 1.4 (.8-2.4) Troch Frx Sup-Ant CtTh 1.6 (.9-2.8) 2.3 (1.1-4.6) Inf-Post CtTh - 2.4 (1.3-4.5) FN abmd 1.5 (.8-2.7) 1.5 (.7-3.1) Johannesdottir et al, Bone 211 QCT for Monitoring Treatment Response: Changes in Spine Bone Density by DXA and QCT: the PaTH trial Mean Change (%) 4 3 2 1 Black et al, NEJM, 23 abmd by DXA PTH PTH/ALN ALN vbmd by QCT (Trabecular) 5

Changes in proximal femur after teriparatide by DXA or QCT (52 postmenopausal women in EUROFORS trial) Imaging Approaches Change vs baseline (%) 6 4 2 12 mo 24 mo Macroarchitecture / Bone Geometry Microarchitecture High-res peripheral computed tomography (HR-pQCT) Magnetic resonance imaging (MRI) -2-4 Neck BMD Trab vbmd Cort vbmd Cort Area DXA QCT p<.5, p<.1 vs BL Borggrefe et al, JBMR 21 High Resolution pqct (X-treme CT, Scanco Medical AG) ~ 82 µm 3 voxel size ~ 3 min scan time, < 4 µsv Distal Radius Distal Tibia Reproducibility: density:.7 to 1.5% structure: 1.5-4.4 Peripheral skeleton only Specialized equipment Boutroy, et al, JCEM 25 6

Separation of cortical and trabecular compartments HR-pQCT discriminates osteopenic women with and without history of fragility fracture (age = 69 yrs, n=35 with prev frx, n=78 without fracture) Fracture vs No Fracture, % Difference 3 25 2 15 1 5-5 -1-15 Spine -.3 BMD.4 Femoral Neck Boutroy et al, JCEM (25) 3 25 2 15 1 5-5 -1-15 BV/TV TbN TbTh TbSp TbSpSD -5.6 p <.5 vs fracture free controls -12.4 HR-pQCT at the Radius -8.5 12.8 25.6 Worse bone architecture in premenopausal women with distal radius fracture (4 premenopausal wrist fx, 8 age-matched controls) P <.5 P <.5 UDR adj Wrist Frx Osteopenic by DXA BMD Distal Tibia (7 yr old woman) Fx - Cont (%) DXA HR-pQCT Control Distal Radius Rozental et al, JBJS (submitted) Images courtesy of S. Boutroy & P. Delmas, Inserm U831, Lyon 7

hr-pqct shows increased cortical porosity in postmenopausal women Cortical porosity and pathophysiology of fragility in Type II Diabetes? Cortical porosity 2 to 4-fold higher in postmenopausal vs premenopausal women Nishiyama et al, JBMR 21 Burghardt et al, JBMR 21 Control Diabetes Diabetes + Frx T2DM have same or higher BMD, but markedly higher (+36 to 12%) cortical porosity vs controls Burghardt et al, J Clin Endo Metab (21) Geometry Non-invasive Imaging Approaches DXA-based Hip Structural Analysis (HSA) Quantitative Computed Tomography (QCT) Microarchitecture High-res peripheral computed tomography (hr-pqct) High-res magnetic resonance imaging (MRI) MRI Assessment of Trabecular Bone Architecture Features / Advantages of MRI Nonionizing radiation 3-D Clinical scanners Images depict marrow, whereas bone has no signal 15 x 15 x 3 µm Disadvantages Technically demanding Expensive, time consuming Precision Problem for claustrophobics! 8

What does the future hold for MRI? 3T Axial skeleton and hip? Better signal-to-noise ratio Shorter Imaging time Less motion artifact Higher resolution Images courtesy of Sharmila Majumdar, UCSF Non-invasive Imaging Approaches Geometry DXA-based Hip Structural Analysis (HSA) Quantitative Computed Tomography (QCT) Microarchitecture High-res peripheral computed tomography (hr-pqct) High-res magnetic resonance imaging (MRI) Bone strength Finite element analysis (FEA) 3D QCT Geometry + vbmd Prediction of bone strength Prediction of Bone Strength Using Finite Element Analysis (FEA) Approach: QCT-based Finite Element Model Standard engineering approach to evaluate mechanical behavior of complex structures 3D geometry Integrates material and structural information from 3D QCT and hr-pqct Can provide multiple strength metrics material properties Cadaver studies show that FEA predicts femoral and vertebral strength better than BMD (Cody 1998; Pistoia 22; Crawford 24) Has been used in vivo to study effect of treatment on bone strength and predict fracture risk Image courtesy of T. Keaveny Ultimate Strength QCT Density Crawford, et al, Bone 23 9

QCT-based FEA models of proximal femur FEA and femoral strength Intertroch Fx Fem Neck Fx FEA-predicted strength strongly correlated with experimentally measured femoral strength in sideways fall configuration (sideways fall configuration, 73 femurs, aged 55 to 98 yrs) Bouxsein 1999 Femoral strength declines more than femoral BMD (~ 5 M and W per decade, Mayo cohort) Femoral Strength (N) 1 8 6 4 2 r 2 =.78 p <.1 2 4 6 8 1 FEA-Predicted Femoral Strength (N) Women Men STRENGTH (N) 6 5 4 3 2 1 Femoral Strength FEMALE MALE 3 4 5 6 7 8 9 AGE -55% W -39% M abmd (g/cm^2) 1.2 1..8.6.4.2. Femoral BMD FEMALE MALE 3 4 5 6 7 8 9 AGE -26% W -21% M Keaveny, et al, JBMR 21 1

QCT-based FEA and clinical vertebral frx in men 63 Clin Fx, 242 No Frx Controls: Hazard ratios per SD reduction All models adjusted for age, BMI, race FEA and Clinical Vertebral Fracture in Men 63 Clin Fx, 242 No Frx Controls: Hazard ratios per SD reduction All models adjusted for age, BMI, race HR per SD DXA - L Spine BMD 3.4 (2.4 4.7) DXA - Fem Neck BMD 2.1 (1.5 3.) HR per SD Adj LS BMD DXA - L Spine BMD 3.4 (2.4 4.7) -- DXA - Fem Neck BMD 2.1 (1.5 3.).9 (.6-1.4) QCT - Integral vbmd 5.8 (3.9 8.7) QCT - Integral vbmd 5.8 (3.9 8.7) 9.4 (5.1-17.4) FEA - Vert Strength 7.3 (4.6-11.4) FEA - Vert Strength 7.3 (4.6-11.4) 8.5 (4.5-16.2) Keaveny et al, ASBMR 21 Keaveny et al, ASBMR 21 QCT-based finite element analysis of hip vs femoral BMD for prediction of hip fracture VFx Case Str = 4656 N Control Str = 695 N Older men (Mr OS) 1 4 hip fx vs 21 controls Men and women (AGES) 2 199 hip fx vs 724 control Hazard Ratio (95% CI) Femoral BMD QCT-FEA strength 4.4 (2.4-9.1) 6.5 (2.3-18.3) 3.3 (2.8-4.1) 4.1 (3.4-5.2) Adjusted for age, BMI, race Melton et al, JBMR 28 1 Orwoll et al, JBMR 29; 2 Kopperdahl et al, ASBMR 21 11

QCT-based FEA Effect of ibandronate treatment on femoral strength (~ 4 postmenopausal women / group, 12 mo tmt, mean ± 95% CI) QCT-based FEA Effect of denosumab on femoral strength (48 PBO, 51 denosumab, 36 mo tmt, mean ± 95% CI) % Change at 12 mo in femoral strength vs BL 6 Placebo Ibandronate 4 2-2 -4-6 -8 p<.5 vs baseline (% Change vs BL) 2 16 12 8 4-4 -8-12 Femoral Strength Placebo Denosumab 12 mo 24 mo 36 mo -5.4% +8.4% Lewiecki, et al JCEM 29 Keaveny et al, ASBMR 21 p<.5 vs baseline QCT-based Finite Element Analysis: Effect of denosumab on femoral and vertebral strength (48 PBO, 51 denosumab, 36 mo tmt, mean ± 95% CI) Discrimination of wrist fx subjects by FEA Fracture Control (% Change vs BL) 2 16 12 8 4-4 -8-12 Femoral Strength Placebo Denosumab 12 mo 24 mo 36 mo 2 16 12 8 4-4 -8-12 Vertebral Strength 12 mo 24 mo 36 mo distal proximal MPa 2 Estimated failure load 4-15% 3 2 1 CON FX Keaveny et al, ASBMR 21 p<.5 vs baseline Boutroy et al, JBMR 28 12

Considerations for applying FEA to clinical studies Loading conditions? Falls are variable Activities that cause vertebral fx largely unknown Role of intervertebral disk degeneration? Assume relationship between QCT-density and tissue mechanical properties Clinical QCT does not reflect sub-mm trabecular architecture or cortical porosity Non-invasive assessment of bone strength: where are we today? Several techniques show promise for noninvasive assessment of bone microarchitecture and strength. For clinical research -- YES! Pathophysiology For clinical trials -- YES! Differentiate mechanism of action For routine clinical practice -- NOT YET! Need standardization, reference data, prospective studies Beyond BMD what is the hope for new non-invasive imaging tools? Gain insight into pathophysiology of disease and effects of treatments Enhance identification of those at greatest risk for fracture Improve monitoring of treatment response Serve as endpoints for fractures in clinical trials Prev Frx Age Understanding Fracture Risk: Today and Tomorrow BMD Bone Turnover Bone Mass Distribution SKELETAL FRAGILITY Damage QCT, MRI, HRCT FEA Micro- Architecture Collagen Mineralization 13

Thank you for your attention Acknowledgements Sharmila Majumdar Andrew Burghardt Tony Keaveny David Kopperdahl Femoral neck cortical thickness varies around neck circumference Cortical porosity and trabecularization of the endocortical surface with age 29 yr Bone loss (mg/ha) Cortical Trabecular 67 yr 9 yr Zebaze et al, Lancet 21 5-64 65-79 > 8 yrs Prior studies have likely underestimated cortical bone loss 14